On 13th March, the United Kingdom (UK) Parliament voted in favour of leaving the European Union (EU) with a Brexit deal. A further vote took place on 14th March in favour of extending Article 50 (the UK/EU Withdrawal Agreement) beyond 29th March, however this will now require agreement from EU leaders at an EU Summit on 21st March.
We are writing to you today as there still remain a number of potential outcomes to Brexit. As we have previously communicated, PCI Pharma Services has a robust ‘Brexit plan’ to ensure the continuity of EU supply chains. This plan included the acquisition of an EU facility (Millmount Healthcare), located near Dublin, Ireland with the construction of a Clinical Storage & Distribution facility and a full analytical release testing laboratory allowing method transfer for release of Commercial products.
Irrespective of the final outcome, PCI Pharma Services has always committed to ensuring that the security of your supply chain and management of your products will be maintained via our UK sites and our EU facility.
As the Brexit situation evolves over the coming days and weeks, we expect to gain additional clarity and will be communicating with you and advising of any implications to your supply chains. However, in the meantime should you have any questions, please contact either your Project Manager, Commercial Account Manager, Business Development Manager or the PCI Brexit team (Brexit@pci.com).